International Clinical Trial: A Randomized, Open-label, Crossover Bioequivalence Study of Generic Imatinib Tablet 400 mg and Reference Product Imatinib Tablet 400 mg in Healthy Thai Volunteers under Fed Conditions

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (TCTR20250812002) titled 'A Randomized, Open-label, Crossover Bioequivalence Study of Generic Imatinib Tablet 400 mg and Reference Product Imatinib Tablet 400 mg in Healthy Thai Volunteers under Fed Conditions' on Aug. 12.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: Bio-innova Co., Ltd.

Condition: The study is conducted in healthy Thai human volunteers to treatment the overall incidence of chronic myeloid leukemia Bioequivalence Imatinib Tablet 400 mg Bioequivalence Imatinib Tablet 400 mg

Intervention: The new generic products which were recently developed. Volunteer will receive a single dose of Generic Im...